Skip to main content

Table 1 Clinicopathologic characteristics of serous ovarian cancer

From: Age is associated with prognosis in serous ovarian carcinoma

Characteristic ≥ 65 years N (%) < 65 years N (%) p #
Baseline CA-125 (U/mL, meida, range) 960 (7–34,000) 840 (7–30,900) 0.55
Body Mass Index (mean SD) 24.1 (3.1) 25.4 (3.8) 0.04
Grade
 High 106 (96.4) 178 (87.3) 0.02
 Low 4 (3.6) 26 (12.7)
FIGO* stage
 I 3 (2.7) 5 (2.5) 0.84
 II 8 (7.3) 10 (4.9)
 III 75 (68.2) 146 (71.6)
 IV 24 (21.8) 43 (21.1)
ECOG PS*
 0 44 (40.0%) 104 (51.0%) 0.03
 1 47 (42.7%) 83 (40.7%)
  ≥ 2 19 (17.3%) 17 (8.3%)
Primary treatment
 NAC* 31 (28.2%) 30 (14.7%) 0.00
 PDS 50 (45.5%) 151 (74.0%)
 Chemotherapy only 18 (16.4%) 8 (3.9%)
 No Treatment 11 (10.0%) 15 (7.4%)
Surgical residual
 Optimal 44 (54.3%) 123 (68.0%) 0.04
 Suboptimal 33 (40.7%) 48 (26.5%)
 Unknown 4 (5.0%) 10 (5.5%)
Recurrence free interval (months)
  ≤ 12 34 (47.2%) 56 (35.7%) 0.13
  > 12 38 (52.8%) 101 (64.3%)
  1. p #, Chi-square P-value; Baseline&, Level at diagnosis; FIGO*, the International Federation of Gynecology and Obstetrics; ECOG PS*, ECOG Eastern Cooperative Oncology Group Performance Status; NAC*, Neoadjuvant chemotherapy; Optimal cytoreduction, the absence of macroscopic disease on the completion of the surgical procedure